Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system

Hazel Clothier, Laine Hosking, Nigel Crawford, Melissa Russell, Mee Lee Easton, Julie-Ann Quinn, James Peter Buttery

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.
Original languageEnglish
Pages (from-to)79 - 86
Number of pages8
JournalDrug Safety
Volume38
Issue number1
DOIs
Publication statusPublished - 2015

Cite this

Clothier, Hazel ; Hosking, Laine ; Crawford, Nigel ; Russell, Melissa ; Easton, Mee Lee ; Quinn, Julie-Ann ; Buttery, James Peter. / Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system. In: Drug Safety. 2015 ; Vol. 38, No. 1. pp. 79 - 86.
@article{38c9d047f92d49239870b50d318f66da,
title = "Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system",
abstract = "Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.",
author = "Hazel Clothier and Laine Hosking and Nigel Crawford and Melissa Russell and Easton, {Mee Lee} and Julie-Ann Quinn and Buttery, {James Peter}",
year = "2015",
doi = "10.1007/s40264-014-0248-6",
language = "English",
volume = "38",
pages = "79 -- 86",
journal = "Drug Safety",
issn = "0114-5916",
publisher = "Springer-Verlag London Ltd.",
number = "1",

}

Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system. / Clothier, Hazel; Hosking, Laine; Crawford, Nigel; Russell, Melissa; Easton, Mee Lee; Quinn, Julie-Ann; Buttery, James Peter.

In: Drug Safety, Vol. 38, No. 1, 2015, p. 79 - 86.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system

AU - Clothier, Hazel

AU - Hosking, Laine

AU - Crawford, Nigel

AU - Russell, Melissa

AU - Easton, Mee Lee

AU - Quinn, Julie-Ann

AU - Buttery, James Peter

PY - 2015

Y1 - 2015

N2 - Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.

AB - Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.

UR - http://link.springer.com/article/10.1007%2Fs40264-014-0248-6

U2 - 10.1007/s40264-014-0248-6

DO - 10.1007/s40264-014-0248-6

M3 - Article

VL - 38

SP - 79

EP - 86

JO - Drug Safety

JF - Drug Safety

SN - 0114-5916

IS - 1

ER -